Back to Search Start Over

Machine learning in primary biliary cholangitis: A novel approach for risk stratification

Authors :
Gerussi, A
Verda, D
Bernasconi, D
Carbone, M
Komori, A
Abe, M
Inao, M
Namisaki, T
Mochida, S
Yoshiji, H
Hirschfield, G
Lindor, K
Pares, A
Corpechot, C
Cazzagon, N
Floreani, A
Marzioni, M
Alvaro, D
Vespasiani‐gentilucci, U
Cristoferi, L
Valsecchi, M
Muselli, M
Hansen, B
Tanaka, A
Invernizzi, P
Gerussi, Alessio
Verda, Damiano
Bernasconi, Davide Paolo
Carbone, Marco
Komori, Atsumasa
Abe, Masanori
Inao, Mie
Namisaki, Tadashi
Mochida, Satoshi
Yoshiji, Hitoshi
Hirschfield, Gideon
Lindor, Keith
Pares, Albert
Corpechot, Christophe
Cazzagon, Nora
Floreani, Annarosa
Marzioni, Marco
Alvaro, Domenico
Vespasiani‐Gentilucci, Umberto
Cristoferi, Laura
Valsecchi, Maria Grazia
Muselli, Marco
Hansen, Bettina E.
Tanaka, Atsushi
Invernizzi, Pietro
Gerussi, A
Verda, D
Bernasconi, D
Carbone, M
Komori, A
Abe, M
Inao, M
Namisaki, T
Mochida, S
Yoshiji, H
Hirschfield, G
Lindor, K
Pares, A
Corpechot, C
Cazzagon, N
Floreani, A
Marzioni, M
Alvaro, D
Vespasiani‐gentilucci, U
Cristoferi, L
Valsecchi, M
Muselli, M
Hansen, B
Tanaka, A
Invernizzi, P
Gerussi, Alessio
Verda, Damiano
Bernasconi, Davide Paolo
Carbone, Marco
Komori, Atsumasa
Abe, Masanori
Inao, Mie
Namisaki, Tadashi
Mochida, Satoshi
Yoshiji, Hitoshi
Hirschfield, Gideon
Lindor, Keith
Pares, Albert
Corpechot, Christophe
Cazzagon, Nora
Floreani, Annarosa
Marzioni, Marco
Alvaro, Domenico
Vespasiani‐Gentilucci, Umberto
Cristoferi, Laura
Valsecchi, Maria Grazia
Muselli, Marco
Hansen, Bettina E.
Tanaka, Atsushi
Invernizzi, Pietro
Publication Year :
2022

Abstract

Background & Aims: Machine learning (ML) provides new approaches for prognostication through the identification of novel subgroups of patients. We explored whether ML could support disease sub-phenotyping and risk stratification in primary biliary cholangitis (PBC). Methods: ML was applied to an international dataset of PBC patients. The dataset was split into a derivation cohort (training set) and a validation cohort (validation set), and key clinical features were analysed. The outcome was a composite of liver-related death or liver transplantation. ML and standard survival analysis were performed. Results: The training set was composed of 11,819 subjects, while the validation set was composed of 1,069 subjects. ML identified four clusters of patients characterized by different phenotypes and long-term prognosis. Cluster 1 (n = 3566) included patients with excellent prognosis, whereas Cluster 2 (n = 3966) consisted of individuals at worse prognosis differing from Cluster 1 only for albumin levels around the limit of normal. Cluster 3 (n = 2379) included young patients with florid cholestasis and Cluster 4 (n = 1908) comprised advanced cases. Further sub-analyses on the dynamics of albumin within the normal range revealed that ursodeoxycholic acid-induced increase of albumin >1.2 x lower limit of normal (LLN) is associated with improved transplant-free survival. Conclusions: Unsupervised ML identified four novel groups of PBC patients with different phenotypes and prognosis and highlighted subtle variations of albumin within the normal range. Therapy-induced increase of albumin >1.2 x LLN should be considered a treatment goal.

Details

Database :
OAIster
Notes :
STAMPA, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1308944285
Document Type :
Electronic Resource